The pattern and outcome of acute severe colitis.

PubWeight™: 1.06‹?› | Rank: Top 15%

🔗 View Article (PMID 21122540)

Published in J Crohns Colitis on February 19, 2010

Authors

Lotte C Dinesen1, Alissa J Walsh, Marijana Nedeljkovic Protic, Graham Heap, Fraser Cummings, Bryan F Warren, Bruce George, Neil J M Mortensen, Simon P L Travis

Author Affiliations

1: Gastroenterology Unit, John Radcliffe Hospital, Oxford, UK.

Associated clinical trials:

Pharmacokinetics of IFX and TNF Concentrations in Serum, Stool, and Colonic Mucosa in Acute Severe Ulcerative Colitis (PROTOS) | NCT03765450

Articles citing this

Infliximab versus cyclosporine as rescue therapy in acute severe steroid-refractory ulcerative colitis: a systematic review and meta-analysis. Int J Colorectal Dis (2012) 1.05

Strategies for the care of adults hospitalized for active ulcerative colitis. Clin Gastroenterol Hepatol (2012) 1.01

Infliximab versus Cyclosporine Treatment for Severe Corticosteroid-Refractory Ulcerative Colitis: A Korean, Retrospective, Single Center Study. Gut Liver (2015) 0.90

Similar risk of depression and anxiety following surgery or hospitalization for Crohn's disease and ulcerative colitis. Am J Gastroenterol (2013) 0.87

Tacrolimus or infliximab for severe ulcerative colitis: short-term and long-term data from a retrospective observational study. BMJ Open Gastroenterol (2015) 0.85

Current approaches to the management of new-onset ulcerative colitis. Clin Exp Gastroenterol (2014) 0.84

Raman spectroscopy of endoscopic colonic biopsies from patients with ulcerative colitis to identify mucosal inflammation and healing. Biomed Opt Express (2016) 0.81

Systematic Review and Meta-Analysis: Infliximab or Cyclosporine as Rescue Therapy in Patients With Severe Ulcerative Colitis Refractory to Steroids. Am J Gastroenterol (2016) 0.80

Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial. Lancet Gastroenterol Hepatol (2016) 0.79

Predictive factors for a severe clinical course in ulcerative colitis: Results from population-based studies. World J Gastrointest Pharmacol Ther (2016) 0.78

Current best practice for disease activity assessment in IBD. Nat Rev Gastroenterol Hepatol (2016) 0.77

Efficacy and Safety of Tacrolimus Therapy for Active Ulcerative Colitis; A Systematic Review and Meta-analysis. J Crohns Colitis (2015) 0.76

Predicting Outcomes to Optimize Disease Management in Inflammatory Bowel Diseases. J Crohns Colitis (2016) 0.76

Clinical relevance of endoscopic assessment of inflammation in ulcerative colitis: Can endoscopic evaluation predict outcomes? World J Gastroenterol (2016) 0.75

Acute severe ulcerative colitis: from pathophysiology to clinical management. Nat Rev Gastroenterol Hepatol (2016) 0.75

Oral Contraceptive Use and Risk of Ulcerative Colitis Progression: A Nationwide Study. Am J Gastroenterol (2016) 0.75

Systematic review and meta-analysis of third-line salvage therapy with infliximab or cyclosporine in severe ulcerative colitis. Ann Gastroenterol (2016) 0.75

MANAGEMENT OF ACUTE SEVERE ULCERATIVE COLITIS: A CLINICAL UPDATE. Arq Bras Cir Dig (2016) 0.75

Healthcare professionals' views of the use and administration of two salvage therapy drugs for acute ulcerative colitis: a nested qualitative study within the CONSTRUCT trial. BMJ Open (2017) 0.75

Articles by these authors

Acute upper gastrointestinal bleeding in the UK: patient characteristics, diagnoses and outcomes in the 2007 UK audit. Gut (2011) 4.79

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut (2012) 4.24

Mucosal healing in inflammatory bowel diseases: a systematic review. Gut (2012) 3.02

IL23R variation determines susceptibility but not disease phenotype in inflammatory bowel disease. Gastroenterology (2007) 2.97

Use of endoscopy for management of acute upper gastrointestinal bleeding in the UK: results of a nationwide audit. Gut (2010) 2.82

IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J Exp Med (2011) 2.74

A randomized, controlled trial of fibrin glue vs. conventional treatment for anal fistula. Dis Colon Rectum (2002) 2.10

Th17 cells expressing KIR3DL2+ and responsive to HLA-B27 homodimers are increased in ankylosing spondylitis. J Immunol (2011) 1.81

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics. Am J Gastroenterol (2010) 1.74

TUCAN (CARD8) genetic variants and inflammatory bowel disease. Gastroenterology (2006) 1.73

Weight loss at high altitude: pathophysiology and practical implications. Eur J Gastroenterol Hepatol (2006) 1.68

A common CTLA4 haplotype associated with coeliac disease. Eur J Hum Genet (2005) 1.65

Outcome measurement in clinical trials for Ulcerative Colitis: towards standardisation. Trials (2007) 1.62

Diagnosis and outcome of small bowel tumors found by capsule endoscopy: a three-center Australian experience. Am J Gastroenterol (2006) 1.46

Increased frequency of regulatory T cells in peripheral blood and tumour infiltrating lymphocytes in colorectal cancer patients. Cancer Immun (2007) 1.43

Identifying Ureters In Situ Under Fluorescence During Laparoscopic and Open Colorectal Surgery. Ann Surg (2016) 1.39

Obstructing giant post-inflammatory polyposis in ulcerative colitis: Case report and review of the literature. J Crohns Colitis (2008) 1.28

Alterations in the composition of the supramucosal defense barrier in relation to disease severity of ulcerative colitis. J Histochem Cytochem (2006) 1.17

A basal gradient of Wnt and stem-cell number influences regional tumour distribution in human and mouse intestinal tracts. Gut (2012) 1.16

Near-infrared (NIR) perfusion angiography in minimally invasive colorectal surgery. Surg Endosc (2014) 1.16

Consensus for managing acute severe ulcerative colitis in children: a systematic review and joint statement from ECCO, ESPGHAN, and the Porto IBD Working Group of ESPGHAN. Am J Gastroenterol (2011) 1.16

The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety. Am J Gastroenterol (2011) 1.15

Comparison of outcomes after restorative proctocolectomy with or without defunctioning ileostomy. Arch Surg (2008) 1.13

Randomized, double-blind, placebo-controlled trial of sildenafil (Viagra) for erectile dysfunction after rectal excision for cancer and inflammatory bowel disease. Dis Colon Rectum (2002) 1.05

Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment. Dis Colon Rectum (2006) 1.01

The role of CMV in steroid-resistant ulcerative colitis: A systematic review. J Crohns Colitis (2009) 1.00

Revolution and evolution: 30 years of ileoanal pouch surgery. Inflamm Bowel Dis (2006) 0.99

Medical management of Crohn's disease. BMJ (2008) 0.97

Restrictive vs liberal blood transfusion for acute upper gastrointestinal bleeding: rationale and protocol for a cluster randomized feasibility trial. Transfus Med Rev (2013) 0.95

Observer agreement in the diagnosis of serrated polyps of the large bowel. Histopathology (2009) 0.93

Botulinum toxin as second-line therapy for chronic anal fissure failing 0.2 percent glyceryl trinitrate. Dis Colon Rectum (2003) 0.92

Clinical and molecular characteristics of isolated colonic Crohn's disease. Inflamm Bowel Dis (2008) 0.91

Recurrence after abdominal surgery for Crohn's disease: relationship to disease site and surgical procedure. Dis Colon Rectum (2002) 0.89

Prevalence, management, and outcomes of patients with coagulopathy after acute nonvariceal upper gastrointestinal bleeding in the United Kingdom. Transfusion (2012) 0.89

Biosimilars in IBD: hope or expectation? Gut (2013) 0.88

Neoadjuvant therapy for rectal cancer: improved tumor response, local recurrence, and overall survival in nonanemic patients. Dis Colon Rectum (2005) 0.88

Denonvilliers' fascia lies anterior to the fascia propria and rectal dissection plane in total mesorectal excision. Dis Colon Rectum (2005) 0.88

Red blood cell transfusion practice in patients presenting with acute upper gastrointestinal bleeding: a survey of 815 UK clinicians. Transfusion (2011) 0.86

Thiopurine therapy: when to start and when to stop. Eur J Gastroenterol Hepatol (2003) 0.86

What is the optimal treatment for anemia in inflammatory bowel disease? Curr Drug Deliv (2012) 0.85

Risk for colorectal neoplasia in patients with colonic Crohn's disease and concomitant primary sclerosing cholangitis. Clin Gastroenterol Hepatol (2011) 0.85

Modulation of CD103 expression on human colon carcinoma-specific CTL. J Immunol (2007) 0.85

Contribution of histological, serological, and genetic factors to the clinical heterogeneity of adult-onset coeliac disease. Scand J Gastroenterol (2009) 0.83

The European consensus on ulcerative colitis: new horizons? Gut (2008) 0.83

A sweet coating--how bacteria deal with sugars. Adv Exp Med Biol (2003) 0.82

Comparison between prospective and retrospective evaluation of Crohn's disease activity index. Am J Gastroenterol (2005) 0.82

The pathology of diverticular disease. Best Pract Res Clin Gastroenterol (2002) 0.81

Donor Recruitment for Fecal Microbiota Transplantation. Inflamm Bowel Dis (2015) 0.81

How to manage the infectious risk under anti-TNF in inflammatory bowel disease. Curr Drug Targets (2010) 0.79

The connective tissue changes of Crohn's disease. Histopathology (2011) 0.79

Therapy of ulcerative colitis: state of the art. Curr Opin Gastroenterol (2008) 0.79

Conventional drug therapy for inflammatory bowel disease. Scand J Gastroenterol (2015) 0.78

The routine use of histochemical stains in gastrointestinal pathology: a UK-wide survey. Histopathology (2009) 0.78

Mucin expression in the ileoanal reservoir reflects incomplete mucosal adaptation. J Pathol (2002) 0.77

IBD care in Europe: A comparative audit of the inpatient management of Crohn's disease and ulcerative colitis using the national UK IBD audit tool. J Crohns Colitis (2009) 0.77

Recurrent posterior scleritis and orbital myositis as extra-intestinal manifestations of Crohn's disease: Case report and systematic literature review. J Crohns Colitis (2008) 0.77

Role of tumor necrosis factor in Crohn's disease. Curr Opin Investig Drugs (2002) 0.77

An economic evaluation comparing once daily with twice daily mesalazine for maintaining remission based on results from a randomised controlled clinical trial. J Crohns Colitis (2008) 0.76

Tuberculosis and TNF-inhibitors: history of exposure should outweigh investigations. BMJ Case Rep (2014) 0.76

Therapeutic inhibitors of tumor necrosis factor in Crohn's disease. Curr Opin Investig Drugs (2002) 0.76

Nocturnal penile tumescence is diminished but not ablated in postproctectomy impotence. Dis Colon Rectum (2003) 0.76

An economic evaluation comparing concomitant oral and topical mesalazine versus oral mesalazine alone in mild-to-moderately active ulcerative colitis based on results from randomised controlled trial. J Crohns Colitis (2009) 0.76

Acute upper gastrointestinal bleeding: identifying low risk patients. Gut (2012) 0.75

Causality and Chance in the Development of Cancer. N Engl J Med (2015) 0.75

A rare cause of an ileocaecal mass and lymphadenopathy. Gut (2011) 0.75

Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease. J Crohns Colitis (2015) 0.75

Use of a monoclonal antibody to sucrase-isomaltase for evaluation of the columnar cuff after stapled restorative proctocolectomy. Dis Colon Rectum (2007) 0.75

Hog Charm II tetracycline test screening results compared with a liquid chromatography tandem mass spectrometry 10-μg/kg method. J Food Prot (2012) 0.75

IBD and IBS: novel mechanisms and future practice. Preface. Dig Dis (2010) 0.75

Erratum: Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat Med (2017) 0.75